key: cord-0723001-hfq3zct4
authors: Jullien, Maxime; Bourgeois, Amandine Le; Coste-Burel, Marianne; Peterlin, Pierre; Garnier, Alice; Rimbert, Marie; Imbert, Berthe-Marie; Gouill, Steven Le; Moreau, Philippe; Mahe, Beatrice; Dubruille, Viviane; Blin, Nicolas; Lok, Anne; Touzeau, Cyrille; Gastinne, Thomas; Tessoulin, Benoit; Vantyghem, Sophie; Béné, Marie C; Guillaume, Thierry; Chevallier, Patrice
title: B-cell aplasia is the most powerful predictive marker for poor humoral response after BNT162b2 mRNA SARS-CoV-2 vaccines in recipients of allogeneic hematopoietic stem cell transplantation
date: 2022-02-24
journal: Transplant Cell Ther
DOI: 10.1016/j.jtct.2022.02.018
sha: 11438008e9cf4336bfcee5c6f5f405f54669db5c
doc_id: 723001
cord_uid: hfq3zct4

BACKGROUND: : Little is known on the immune response to SARS-CoV-2 vaccination in recipients of allogeneic hematopoietic stem cell transplantation (Allo-HSCT). However, a few studies have reported that adequate protection could be provided to this population. OBJECTIVE(S): : The purpose of this study was to evaluate which factors can predict the efficacy of SARS-CoV-2 vaccination in these specifically immunosuppressed patients. STUDY DESIGN: : Specific anti Spike (S) antibody responses were assessed in a cohort of 117 Allo-HSCT recipients after two injections of BNT162b2 mRNA SARS-CoV-2 vaccine (V1 and V2). Factors considered liable to influence the antibody response and analyzed in this series were the interval between Allo-HSCT and V1, donor source, recipient and donor age, current immunosuppressive/chemotherapy (I/C) treatment and levels of CD4(+)and CD8(+) T-cells, B-cells and NK-cells at the time of V1. RESULTS: : Overall, the S-antibody response rate, evaluated at a median of 35 days after V2, was 82.9% for the entire cohort, with 71 patients (61%) reaching the highest titre. In univariate analysis, a lower pre-V1 median total lymphocyte count, lower CD4+ T-cell and B-cell counts as well as ongoing I/C treatment and a haploidentical donor were characteristic of non-humoral responders. However, multiparameter analysis showed that B-cell aplasia was the only factor predicting the absence of a specific immune response (Odd Ratio 0.01, 95%CI [0.00 – 0.10], p <10(−3)). Indeed, the rate of humoral response was 9.1% in patients with B-cell aplasia, vs 95.9% in patients with a B-cell count higher than 0 (p<10(−9)). CONCLUSION(S): : These results advocate for the prescription of anti-SARS-CoV-2 vaccination in Allo-HSCT recipients as early as peripheral B-cell levels can be detected, suggesting also a need for a close monitoring of B-cell reconstitution after Allo-HSCT.

COVID-19 due to infection by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been responsible for over 4 million of deaths worldwide. Immunocompromised patients such as patients treated for hematologic malignancies, [1] [2] [3] [4] including recipients of allogeneic hematopoietic stem cell transplantation (Allo-HSCT), 5 represent a particularly high-risk population with mortality rates comprised between 25 and 40%. The results of anti-SARS-CoV-2 vaccination are now progressively reported in such patients, showing surprisingly high efficacy around 70-80%, a rate yet lower than that observed in the general population. [6] [7] [8] Recently, Ram et al. 9 published a study dealing with immune responses after anti-SARS-CoV-2 vaccination in a cohort of patients having received infusion of Allo-HSCT or anti-CD19 CAR T-cells. These authors reported a better post-vaccination humoral response in patients with higher levels of peripheral B-cells. In fact, data remain scarce regarding factors predicting the humoral response after such vaccines in immunocompromised hosts. As a consequence, here we retrospectively investigated which factors, including immune status at time of vaccination, might influence the post-vaccination antibody response after Allo-HSCT.

The main objective of the study was to decipher which factors can predict the humoral response after two injections (V1 and V2) of BNT162b2 (Pfizer-BioNTech) vaccine in a cohort of 117 Allo-HSCT recipients. The characteristics and outcomes of these patients have been already reported. 7, 8 Antibody response to the SARS-CoV-2 spike (S) protein receptor-binding domain was tested (Roche Elecsys®, Rotkreuz, Switzerland) at a median of 35 days (range: 18-77) post-V2. As recommended by the manufacturer, titres ≥0.8 U/mL were considered positive, the highest value being >250 U/mL. 

The 117 Allo-HSCT recipients enrolled ( Table 1) were vaccinated between January 20 and April 17, 2021.

Briefly, their median age was 57 years, with a predominance of male subjects (60%) and treatment for a myeloid disease (66%). Donor source was matched in 67.5% of cases, and haploidentical in 30.8%. Two patients who received a graft from a 9/10 mismatched unrelated donor were not considered for vs 914 days, p <10 -5 ) and lower pre-V1 median total lymphocyte counts (0.62 vs 1.61x10 9 /L, p < 10 -4 ).

Regarding lymphocyte subsets, NHR displayed lower median CD3 (0.39 vs 0.97 x10 9 /L, p = 0.01), CD4

(0.13 vs 0.35 x10 9 /L, p<10 -3 ), and B-cell (0.00 vs 0.28 x10 9 /L, p <10 -6 ) counts. NK and T CD8 counts were not statistically lower in NHR (respectively 0.14 vs 0.21 x10 9 /L, p=0.14 and 0.23 vs 0.45 x10 9 /L, p=0.06). In multivariate analysis (Figure 1 ) also including D0-V1 interval, donor source, current I/C treatment and TCD4 lymphocyte count, only B-cell aplasia remained statistically associated with lack of antibody response after two vaccine injections (Odd Ratio 0.01, 95%CI [0.00 -0.10], p <10 -3 ). The rate of humoral response was 9.1% in patients with B-cell aplasia, vs 95.9% in patients with a B-cell count higher than 0 (p<10 -9 ).

The characteristics of patients with B-cell aplasia (n=11) were compared to those of patients with a documented B-cell count above 0 (n=73). B-cell aplasia was mainly due to rituximab administration post-Allo-HSCT but not to BTK inhibitor or CD19-directed treatments, which both represent only 4 patients.

Indeed, more patients with B-cell aplasia had received rituximab post Allo-HSCT (63% vs 24.7%, p=0.01).

The indication for rituximab was EBV reactivation, except for 2 patients where it was as part of chemotherapy for relapse. The median number of rituximab infusions was not statistically different between patients with or without B-cell aplasia: 6 (IQR: 3.5-6.5) vs 3 (IQR: 2-4), p=0.06, but, as expected, time from the last rituximab infusion was shorter in patients with B-cell aplasia: 6 months (IQR:5. 

This study attempted at identifying factors impairing a protective immune response after anti-SARS-CoV-2 vaccination in Allo-HSCT recipients. The S-antibody response rate post-V2 is high reaching 82.9%

for the entire cohort, 61% reaching the highest titre for this assay and thus probably much higher protective levels. 10 

The authors declare no conflict of interest, except Pr Patrice Chevallier who received honoraria from Pfizer outside the submitted work. Continuous variables are given in median (interquartile range), categorical variables are given as number (percent).

*2 patients received a graft from a 9/10 mis-matched unrelated donor and were not considered for univariate analysis. 

Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study

COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey

Risk factors for a severe form of COVID-19 after allogeneic haematopoietic stem cell transplantation: a Société Francophone de Greffe de Moelle et de Thérapie cellulaire (SFGM-TC) multicentre cohort study

Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients

Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant